- Sol-gel
nose-to-brain system offers superior drug delivery
- New
extraction protocol makes accurate and precise quantification of
cannabinoids possible
- Establishment
of cannabis division to commercialize research developments
A recent release from PreveCeutical Medical Inc. (CSE: PREV)
(OTCQB: PRVCF) (FSE: 18H) shows that, in cannabinoid extraction technology, the
health sciences company is getting it right. The company announced that, during
its soluble gel drug delivery research and development program – the Sol-gel
Program – it had successfully optimized the conditions for extracting
cannabinoids from one of its cannabis strains and developed a proprietary
method – the Extraction Protocol – for the accurate and precise quantification
of cannabinoids present in the extract (http://ibn.fm/iKOST). This technological triumph will allow
PRVCF to generate a range of cannabinoid-based Sol-gel formulations, each with
a distinct, well-defined composition profile, based on specifications from
clinical trial data that determine efficacy and safety. PRVCF is expecting that
its drug delivery Sol-gel system will be employed in a range of therapeutic
applications that target, initially, anxiety, cachexia, chemotherapy-induced
nausea and pain.
The accuracy and precision of PreveCeutical’s Extraction
Protocol has been checked against eight commercial cannabinoid standards over a
broad concentration range. Its validation means that it can now be directly
applied to the four other cannabis strains used in the Sol-gel program. The
Extraction Protocol will expedite the creation of a library of chemically
fingerprinted cannabinoid extracts, each with a complementary cannabinoid
composition. These unique extracts will be optimized and integrated with the
Sol-gel technology for use in a variety of therapeutic applications.
To complement the sophistication of its extraction and
formulation methodologies, PreveCeutical is in search of hardware for its cannabinoid
Sol-gel technology. As Dr. Harry Parekh explained in a recent interview, CBD
Sol-gel is a nose-to-brain delivery system and so optimizing the “spray
profile” is just as important as getting the formulation right (http://ibn.fm/nsv1l).
Formulation and spray profiles go “hand in hand.” PRVCF has been working very
closely with the global leader in spray device manufacture, a company based in
Europe, in a quest for the optimal applicator. PreveCeutical has now narrowed
its choice to two devices that appear to be “optimal for the delivery of the
cannabinoid sol-gels into the nasal cavity.”
Most nasal application methods require “upwards of one or
two dozen sprays, every twenty-hour hours, which is effectively the patient
drinking it, post-nasally.” However, PRVCF believes that its approach will have
the edge, because its spray will gel as soon as it hits the nasal mucosa,
avoiding any post-nasal swallowing, and, therefore, one-to-three applications
per week may be all that is required.
The Sol-gel system is an innovative nose-to-brain drug
delivery platform that holds the promise of making medication regimens more
effective. When therapeutic compounds are taken orally (many are), they travel
through the stomach and intestines and are metabolized, which reduces their
effectiveness. However, the Sol-gel system works by nasal administration and
delivers the therapeutic agent to the mucosal tissue lining the nostrils, where
it is transmitted rapidly to the brain, increasing
bioavailability. Additionally, the gel stays in the nasal passages, slowly
releasing the CBD while keeping it active for up to seven days. This ease of
application and its long-lasting effects may be attractive for patients when
compared to other delivery systems.
PreveCeutical has established a cannabis division to
commercialize its advances with the cannabinoid Sol-gel technology (http://ibn.fm/5SRGc).
“Given the progress we have made with the extractions and
the refined formulations… we believe they can now be channeled into multiple
different dosage forms – wafers, tablets, or sprays – so there’s a whole range
of different applications that we can put the base technology into for a range
of different clinical applications,” Parekh stated in a news release.
For the millions who suffer from anxiety, cachexia,
chemotherapy-induced nausea and pain, this is good news. Clinical trials are
expected to begin by the end of 2019.
For more information, visit the company’s website at www.PreveCeutical.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment